LOS ANGELES, March 5, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
the Company will present at the 30th Annual ROTH Conference on
Monday, March 12th, 2018
at 4:00 p.m. Pacific Daylight Time at
the Ritz-Carlton Laguna Niguel in Dana
Point, California.
A live and archived webcast of the presentation will be
available at http://wsw.com/webcast/roth32/cytr.
About the 30th Annual ROTH Conference
With nearly 550 participating companies and over 4,700
attendees, the ROTH Conference spans four days, from March 11-14, 2018, and will feature presentations
from hundreds of invitation-only public and private companies
representing a variety of sectors including healthcare. This
gathering of institutional investors, private equity investors,
venture capitalists, company executives and service providers has
become a must attend event for anyone working in the small and
mid-cap space. As it has for the past five years, the ROTH
Conference has partnered with the Challenged Athlete's Foundation
to host ROTH's Signature Social Sunday, featuring the ROTH Ride,
Spin, Yoga, Golf & Tennis events.
About the LADR™ Technology Platform
CytRx's innovative LADR™ (Linker Activated Drug Release)
technology platform employs a broad portfolio of novel linker
molecules that selectively bind to circulating albumin and can be
linked to a wide variety of anti-cancer payloads. The Company's
research efforts currently center on creating new molecules from
the combination of ultra-high potency cytotoxic payloads with
tunable linkers. The molecules that CytRx is currently
evaluating concentrate at the tumor site providing targeted
delivery of the cell killing payloads.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a
biopharmaceutical company specializing in research and clinical
development of novel anti-cancer drug candidates that employ linker
technologies to enhance the accumulation and release of drug at the
tumor. CytRx is rapidly expanding its pipeline of
ultra-high potency oncology candidates at its laboratory facilities
in Freiburg, Germany, through its LADR™ (Linker Activated Drug
Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker
technology for the development of a new class of potential
breakthrough anti-cancer
therapies. Aldoxorubicin, CytRx's most advanced drug
conjugate, is an improved version of the widely used anti-cancer
drug doxorubicin and has been out-licensed to NantCell,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to
obtain regulatory approval for its products that use aldoxorubicin;
the ability of NantCell, Inc., to manufacture and
commercialize products or therapies that use aldoxorubicin; the
amount, if any, of future milestone and royalty payments that we
may receive from NantCell, Inc.; our ability to develop new
ultra-high potency drug candidates based on our
LADRTM technology platform; and other risks and
uncertainties described in the most recent annual and quarterly
reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date
of CytRx's most recent annual report. All forward-looking
statements are based upon information available
to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll/Sean Augustine-Obi
(212) 600-1902
michelle@argotpartners.com
sean@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-to-present-at-the-30th-annual-roth-conference-300607718.html
SOURCE CytRx Corporation